What Crystallise does

Crystallise Ltd is a UK-based, founder-led specialist consultancy founded in 2012 by Dr Chris Martin and Dr Alison Martin, headquartered in Colchester, Essex, and operating as a fully remote business within ±2 hours of UK time. The company conducts multidisciplinary evidence synthesis and biomedical modelling work for the pharmaceutical, healthcare, and insurance/pensions sectors, with a 15-20 person team that combines clinicians, health informaticians, actuaries, and senior systematic reviewers. Its core intellectual property centres on two technology platforms: HEORO, a free, continuously curated database of PubMed-indexed HEOR abstracts tagged by trained NLP classifiers, and Evidence Mapper, a subscription platform for AI-assisted abstract screening, shortlisting, indexing and visualisation that is also used as an in-house service deliverable.

The company's service portfolio spans systematic and targeted literature reviews, rapid evidence synthesis, evidence mapping, global value dossiers, health economic modelling, and network meta-analysis for HTA and market access submissions, alongside mortality, longevity, morbidity, and stochastic SEIR infectious disease modelling for life insurers, reinsurers, annuity providers, and catastrophe modellers. It also offers portfolio data enrichment via synthetic sample generation using Spearman Rank Correlation and Cholesky decomposition, plus horizon scanning, and maintains recurring bulletin products (Longevity Perspectives, Geroscience Focus, HTAngel, Newsflash) that support lead generation.

Commercially, Crystallise operates a hybrid model combining project-based professional services (quote-based, typically enterprise scale), a subscription/SaaS revenue stream from Evidence Mapper, freemium exposure through HEORO, and bulletin subscriptions. It is GDPR compliant, holds a UK Data Protection Act registration, and reaches customers globally through direct sales, content marketing, and a partner ecosystem anchored by a long-standing core relationship with JB Medical and supported by collaborations with Imperial College Health Partners, NHS Midlands and Lancashire CSU, Cogentia, Visible Analytics, Simplified Data, and Terminological.

Name

Crystallise

Legal name

Crystallise Ltd

Website

https://crystallise.com

Company type

Private

Founded year

2012

Operating status

Operating

Headcount range

1–10 employees

Short description

Crystallise Ltd is a UK-based specialist consultancy that provides multidisciplinary evidence synthesis and mortality/longevity modelling services to pharmaceutical, healthcare, and insurance/pensions clients, supported by the HEORO abstract database and the Evidence Mapper platform.

Ownership category

akta.pro rank

Product category

Evidence Synthesis & Mortality Modelling Services

NAICS

Scientific Research and Development Services (5417), Other Scientific and Technical Consulting Services (54169)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Real-World Evidence (RWE) & HEOR for Development (HLAIALAI)

akta.pro secondary industries

Mortality, Cause-of-Death Coding & Excess Death Analysis (HLAJAJAG), Diabetes (General) (HLAKADAA), Market Access, Pricing & Reimbursement (Evidence Generation) FSP (HLAGAOAN)

Keywords

• Mortality modelling
• Evidence synthesis services
• Systematic literature reviews
• Health economic modelling
• Longevity risk modelling

Headquarters

HQ city

London

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Marketing or Sales

Revenue model

1. Consulting Services: Project-based consulting engagements for systematic literature reviews, targeted reviews, rapid evidence synthesis, health economic modelling, mortality and longevity modelling for pharmaceutical, healthcare, insurance and pensions clients. Services include HTA submissions support, market access, and regulatory submissions.
2. Evidence Mapper Subscriptions: Subscription-based access to the Evidence Mapper platform for internal literature review projects. Secure client domains with branded access. Provides recurring revenue from agencies and organisations using the platform independently.
3. HEORO Database: Free database platform that generates leads and demonstrates technical capabilities. Not a direct revenue source but supports business development by showcasing indexing and evidence synthesis expertise.
4. Publications and Bulletins: Subscription-based newsletters including Longevity Perspectives, Geroscience Focus bulletins, and HTAngel HTA decisions digest providing recurring engagement with industry professionals.

Pricing tiers

Go-to-market motion2 records

Distribution channels2 records

Marketing channels8 records

Core offering

Crystallise conducts multidisciplinary mortality modelling and evidence synthesis for the pharmaceutical, healthcare, insurance and pensions sectors. Its offerings combine professional consulting services (systematic literature reviews, health economic modelling, mortality and longevity modelling, morbidity modelling, infectious disease modelling) with two proprietary technology products: the HEORO free biomedical abstracts database and the Evidence Mapper subscription platform for AI-assisted literature review and screening.

Product overview

Crystallise offers a suite of evidence synthesis and biomedical modelling products and services for the pharmaceutical, healthcare, and insurance/pensions industries. The core products are HEORO (a free database of PubMed-indexed abstracts on health economics and outcomes research) and Evidence Mapper (a platform for systematic literature reviews with AI-assisted screening). The company provides a comprehensive range of consulting services including systematic literature reviews, targeted reviews, rapid evidence synthesis, evidence mapping, global value dossiers, health economic modelling, network meta-analysis, and synthetic sample generation. For the insurance and pensions sector, services include mortality and longevity modelling, morbidity modelling, infectious disease modelling, horizon scanning, and portfolio data enrichment. The company also publishes industry bulletins including Longevity Perspectives, Geroscience Focus, HTAngel (HTA decisions), and Newsflash.

Differentiator

Problem solved

Functional benefit

Brands

• HEORO: A free database of abstracts of published studies indexed in PubMed relevant to quality of life, costs and resource use and economic evaluations.
• Evidence Mapper

Products and services

• HEORO Database
• Evidence Mapper Platform A subscriber platform providing fast and accurate abstract screening, shortlisting, indexing and visualisation for systematic literature reviews and evidence synthesis. Features an ergonomic screening interface, machine-learning robot-screener software, filtering by country/year/disease subgroup/intervention/methodology/outcome/PRO tools, two-factor authentication, and secure client domains with branded access; available to agencies and organisations running their own literature review projects.
• Pharmaceuticals & Healthcare Consulting Project-based consulting for pharmaceutical and healthcare organisations covering systematic literature reviews, targeted reviews, rapid and micro reviews, evidence mapping, global value dossiers, health economic modelling, network meta-analysis and HTA/market access support.
• Insurance & Pensions Consulting Multidisciplinary consulting for life insurers, reinsurers, bulk annuity providers, pension consultants and catastrophe modellers, covering mortality and longevity modelling, morbidity modelling, infectious disease modelling, portfolio data enrichment and horizon scanning.
• Mortality & Longevity Modelling Cause-of-death mortality and longevity risk modelling service that combines clinical/epidemiological and actuarial expertise. In-house models incorporate socioeconomic and biomedical risk factors (e.g. smoking, BMI) to support Solvency II internal model parameterisation, longevity risk assessment, mortality improvement projections, and tailored annuity underwriting.
• Infectious Disease Modelling Pandemic and infectious disease modelling service using an in-house stochastic SEIR model calibrated for US and UK populations. Produces deterministic scenarios, stochastic event sets and Exceedance Probability curves, with the ability to estimate direct and indirect excess mortality for insured lives.
• Morbidity Modelling Morbidity modelling service delivering advanced pricing and risk assessment tools for disease-specific insurance products, linking high-resolution medical records to morbidity rates.
• Systematic Literature Reviews Full systematic literature review service that identifies and assesses all published literature on a topic, with two-researcher abstract screening and full-text data extraction. Used to support regulatory submissions (e.g. NICE HTA) and peer-reviewed journal publications.
• Targeted Literature Reviews Targeted literature review service that delivers a broad summary of the most important evidence on a specific research question, screening potentially relevant publications and prioritising high-quality studies with outcomes of greatest interest to the client.
• Rapid Evidence Synthesis Rapid and micro evidence synthesis service providing a quick overview of literature at abstract level, with templated slide decks typically delivered within 4-6 weeks to support business development activities.
• Evidence Mapping Evidence mapping service that delivers a dynamic summary of the evidence base with filtering and drill-down capabilities, identifying research gaps and providing an overview of the evidence landscape.
• Health Economic Modelling Health economic modelling service using a flexible, evidence-based and clinically informed approach for complex diseases and health outcomes, supporting Health Technology Assessments and population-based intervention modelling (e.g. stochastic diabetes model).
• Network Meta-Analysis Network meta-analysis service that compares multiple treatments simultaneously using sophisticated statistical analyses, synthesising data from various sources to support strategic decision-making.
• Global Value Dossiers Comprehensive market access deliverable presenting the evidence supporting the value story for a pharmaceutical product, including slide decks, objection handlers and other leave-pieces for payer engagement.
• Synthetic Sample Generation Service that uses Spearman Rank Correlation and Cholesky decomposition to create synthetic portfolios that accurately reflect real-world populations, generating samples of 1 million individuals mirroring Health Survey for England characteristics within 0.5% accuracy.
• Portfolio Data Enrichment Portfolio data enrichment service using sophisticated imputation techniques to estimate portfolio biometrics and risk factor data, enabling insurance clients to enrich their policyholder data for pricing, underwriting and risk assessment.
• Horizon Scanning Horizon scanning service that monitors key medical technologies and future developments by quantifying medical progress over time, using data sources including technology patents, biomedical research and clinical trials. Delivered as semi-annual reports covering biomedical research, medical technologies and longevity factors for life insurer portfolio risk management.
• HTAngel HTA Newsletter Monthly free newsletter summarising the latest decisions on new technologies from Health Technology Assessment (HTA) bodies around the world, providing market-access intelligence to pharmaceutical and healthcare subscribers.
• Longevity Perspectives Bulletin Subscription bulletin providing in-depth analysis and insights into factors influencing life expectancy, covering trends, mortality factors and forecasting for the actuarial industry.
• Geroscience Focus Bulletin Subscription bulletin providing accessible yet rigorous overviews of key topics in geroscience that may influence human health and lifespan, targeting insurance industry executives and longevity risk modellers.
• Longevity Newsflash Monthly complimentary digest highlighting newly published peer-reviewed studies and key updates from public health and statistical agencies for the insurance and pensions industry.

Quantifiable outcome

• Over 100 scientific literature reviews completed since 2012
• +1 more outcomes

Named customers9 records

Segments3 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature5 records

Partnerships

Five partnerships are on record, tiered core, secondary and minor.

• JB MedicalcoreStrategic or Co-development PartnerLong-standing and close collaborative relationship. JB Medical specializes in health economic modelling and market access support. Companies have worked together on many projects over the years.
• Imperial College Health PartnerssecondaryStrategic or Co-development PartnerStrategic partnership for healthcare innovation and research collaboration.
• NHS Midlands and Lancashire Commissioning Support UnitsecondaryStrategic or Co-development PartnerCollaboration with NHS commissioning support unit for healthcare evidence and modelling projects.
• CogentiaminorStrategic or Co-development PartnerHealthcare consultancy collaboration.
• Visible AnalyticsminorStrategic or Co-development PartnerAnalytics consultancy partnership.

Scale indicators3 records

Recent moves5 records

Expansion highlights6 records

Broad incumbents

• Hymans Robertson: Large UK actuarial and pensions consultancy with longevity risk modelling capability. Competes for the same life insurance and bulk annuity mortality/longevity work as Crystallise, but as part of a much broader pensions, insurance, and investment practice.

Direct peers

• Evidera: Global HEOR, HTA, and evidence synthesis consultancy (now part of Thermo Fisher/PPD). Direct competitor for Crystallise's pharma systematic review, HTA submission, and market access work, though Evidera operates at much larger scale and global footprint.
• Cytel: Biostatistics and evidence synthesis consultancy providing systematic reviews, real-world evidence, and HTA support to pharma and biotech. Comparable in evidence synthesis and clinical research services though much larger.
• DRG Abacus (Clarivate): Health economics, outcomes research, and systematic review consultancy now part of Clarivate. Direct competitor in evidence synthesis, HTA submissions, and value dossiers for pharmaceutical clients globally.
• York Health Economics Consortium (YHEC): University of York spin-out providing HEOR, systematic review, and HTA services to pharma, biotech, and public sector clients. UK-based and directly comparable to Crystallise's pharmaceutical consulting arm.
• Covalence Research: HEOR and market access consultancy offering systematic literature reviews, HTA submissions, and value communication. Overlaps closely with Crystallise's pharmaceutical evidence synthesis and global value dossier services.
• Club Vita: Specialist longevity risk analytics provider serving UK and Canadian pension schemes and insurers. Direct peer for Crystallise's mortality and longevity modelling services targeting the insurance and pensions sector.
• JB Medical: UK-based health economic modelling and market access consultancy. Both a strategic partner of Crystallise and a comparable peer, competing for similar HTA and market access work in the UK and Europe.

Emerging players

• Visible Analytics: UK healthcare analytics consultancy partnered with Crystallise. Smaller peer with overlapping health analytics and evidence capabilities, comparable as a niche UK-based analytics specialist.
• Cogentia: UK healthcare consultancy partnered with Crystallise. Comparable as a small UK firm operating in healthcare evidence, market access, and consulting for pharma and NHS clients.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• YouTubeyoutube.com/channel/UCSmT8lXpJNB1vQ8bHTGEmTQ/videos
• LinkedInlinkedin.com/company/crystallise-ltd
• Xx.com/crystallisel
• Facebookfacebook.com/Crystallise-Limited-475740162448919

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Crystallise